Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SPHK2 | Q9NRA0 | 1/20 | 1.00 |
| ▸ | ACHE | P22303 | 1/20 | 0.58 |
| ▸ | GSK3B | P49841 | 15/20 | 0.56 |
| ▸ | MEN1 | O00255 | 1/20 | 0.52 |
| ▸ | NPC1 | O15118 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.52 |
| ▸ | RAB9A | P51151 | 1/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.49 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17377392 | 0.85 | SPHK2 (0.74) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL3532271 | 0.85 | SPHK2 (0.74) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL19075484 | 0.85 | SPHK2 (0.74) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL28615859 | 0.84 | GSK3B (0.78) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL17377349 | 0.84 | GSK3B (0.78) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL17377338 | 0.81 | GSK3B (0.75) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL17377376 | 0.81 | GSK3B (0.86) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL13171355 | 0.76 | ACHE (0.67) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL3534097 | 0.74 | SPHK2 (0.59) | SPHK2ACHEGSK3BMEN1NPC1 | |
| SCHEMBL24176593 | 0.74 | ACHE (0.59) | SPHK2ACHEGSK3BMEN1NPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9828351-B2 | Enzyme interacting agents | MONASH UNIVERSITY (AU) | 2017-11-28 | — | — | US | disclosed |
| US-9828351-B2 | Enzyme interacting agents | MONASH UNIVERSITY (AU) | 2017-11-28 | — | — | US | disclosed |
| US-20170190698-A1 | ENZYME INTERACTING AGENTS | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (AU) | 2017-07-06 | — | — | US | disclosed |
| US-20170190698-A1 | ENZYME INTERACTING AGENTS | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (AU) | 2017-07-06 | — | — | US | disclosed |
| US-20170190698-A1 | ENZYME INTERACTING AGENTS | CENTRAL ADELAIDE LOCAL HEALTH NETWORK INCORPORATED (AU) | 2017-07-06 | — | — | US | disclosed |
| EP-3160949-A1 | ENZYME INTERACTING AGENTS | Monash University (AU) | 2017-05-03 | — | — | EP | disclosed |
| WO-2015196258-A1 | ENZYME INTERACTING AGENTS | MONASH UNIVERSITY (AU) | 2015-12-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170190698-A1 | ENZYME INTERACTING AGENTS | SMPD1, SMPD2, ASAH1 | SPHK2 155/4885ACHE 430/4885GSK3B 3195/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.